Illumina Q1 Beats on NovaSeq X Demand, Raises Guidance, Authorizes $1.5B Buyback
ILMN sits 62% above its 52-week low of $73.86.
Summary
Illumina reported robust first-quarter results, surpassing analyst expectations for both revenue and adjusted EPS, primarily driven by strong demand for its NovaSeq X platform. The company also raised its full-year revenue guidance to $4.52-$4.62 billion and lifted its 2026 non-GAAP diluted EPS guidance to $5.15-$5.30. Significantly, the board authorized a new $1.5 billion share buyback program. This strong financial performance, improved outlook, and substantial capital return initiative are highly positive catalysts for the stock, signaling management's confidence in future growth. Investors will be watching for continued momentum in NovaSeq X sales and the execution of the share repurchase program.
At the time of this announcement, ILMN was trading at $119.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19.3B. The 52-week trading range was $73.86 to $155.53. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.